### Highlights of This Issue 5145

#### SPECIAL FEATURES

**CCR Translations**

- **5147** Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!
  Maria G. Castro, Gregory J. Baker, and Pedro R. Lowenstein
  See related article, p. 5290

**CCR New Strategies**

- **5150** New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances
  Joyce Liu and Ursula A. Matulonis

**Molecular Pathways**

- **5157** Molecular Pathways: Myeloid Complicity in Cancer
  Ingunn M. Stromnes, Philip D. Greenberg, and Sunil R. Hingorani

**CCR Focus**

- **5172** The Lymphoma Medicine Cabinet
  Susan E. Bates

- **5173** Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context
  Owen A. O’Connor and Kensei Tobinai

- **5182** Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype
  Kieron Dunleavy, Mark Roschewski, and Wyndham H. Wilson

- **5194** New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?
  Martin Dreyfing, Simone Ferrero, Niklas Vogt, and Wolfram Klaipper on behalf of the European Mantle Cell Lymphoma Network

**Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas**
Emanuele Zucca, Francesco Bertoni, Barbara Vannata, and Franco Cavalli

**Human T-cell Lymphotropic Virus Type I-Associated Adult T-cell Leukemia-Lymphoma: New Directions in Clinical Research**
Kunihiro Tsukasaki and Kensei Tobinai

**Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?**
Emmanuel Bachy and Gilles Salles

**Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice**
Owen A. O’Connor, Govind Bhagat, Karthik Ganapathi, Martin Bjerregaard Pedersen, Francesco D’Amore, Dejan Radeski, and Susan E. Bates

**CANCER THERAPY: CLINICAL**

- **5255** A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
  Timothy S. Pardee, King Lee, John Luddy, Claudia Maturo, Robert Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, and Bayard L. Powell

**PERSONALIZED MEDICINE AND IMAGING**

- **5265** Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
  Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, and W. Fraser Symmans
Table of Contents

5272 Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Trine Tramm, Hayat Mohammed, Simen Myhre, Marianne Kyndt, Jan Alsner, Anne-Lise Borresen-Dale, Therese Sørlie, Arnoldo Frigessi, and Jens Overgaard

5281 Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer
Kenneth H. Yu, Mark Ricigliano, Manuel Hidalgo, Ghassan K. Abou-Alfa, Maeve A. Lowery, Leonard B. Saltz, Joseph F. Crotty, Kristen Gary, Brandon Cooper, Rena Lapidus, Mariola Sadowska, and Eileen M. O’Reilly

5290 Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright, Alan L. Chang, Mahua Dey, Irina V. Balyasnikova, Chung Kwon Kim, Alex Tobias, Yu Cheng, Julius W. Kim, Jian Qiao, Lingjiao Zhang, Yu Han, and Maciej S. Lesniak
See related commentary, p. 5147

5302 Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Jing Xia, Bruce J. Trock, Roman Gulati, Leslie Mallinger, Matthew R. Cooperberg, Peter R. Carroll, H. Ballentine Carter, and Ruth Etzioni

5311 Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer
Stefan Peter, Edyta Borkowska, Ross M. Drayton, Callum P. Rakhit, Aidan Noon, Wei Chen, and James WF Catto

5322 Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

5331 Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study
Tammy Ho, Lauren E. Howard, Adriana C. Vidal, Leah Gerber, Daniel Moreira, Madeleine McKeever, Gerald Andriolo, Ramiro Castro-Santamaria, and Stephen J. Freedland

CORRECTION

5339 Correction: Targeting miR21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
ABOUT THE COVER

The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal, low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on page 5311 of this issue.